Royalty Pharma Purchased Credit Deteriorated Loans increased by 1.5% to $17.32B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 10.0%, from $15.75B to $17.32B. Over 5 years (FY 2020 to FY 2025), Purchased Credit Deteriorated Loans shows an upward trend with a 5.7% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
High levels indicate exposure to risky loan portfolios acquired via M&A, requiring careful monitoring for potential credit losses.
These are loans acquired through business combinations that showed evidence of credit quality deterioration since their...
Rare for industrial firms; typically found in financial services or companies with significant captive finance arms.
bank_purchased_credit_deteriorated_loans| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $13.53B | $14.59B | $14.33B | $14.04B | $14.06B | $14.96B | $14.18B | $14.27B | $14.00B | $13.97B | $14.83B | $14.13B | $14.64B | $15.73B | $15.91B | $15.75B | $15.98B | $16.62B | $17.06B | $17.32B |
| QoQ Change | — | +7.9% | -1.8% | -2.1% | +0.2% | +6.4% | -5.2% | +0.6% | -1.9% | -0.2% | +6.1% | -4.7% | +3.6% | +7.5% | +1.1% | -1.0% | +1.5% | +4.0% | +2.6% | +1.5% |
| YoY Change | — | — | — | — | +3.9% | +2.5% | -1.0% | +1.7% | -0.5% | -6.6% | +4.5% | -1.0% | +4.6% | +12.6% | +7.3% | +11.5% | +9.1% | +5.7% | +7.2% | +10.0% |